Skip to main content
Have a personal or library account? Click to login
Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy Cover

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

Radiology and Oncology
Volume 49 (2015): Issue 4 (December 2015)
By: ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,   and    
Open Access
|Nov 2015
References

References

  1. 1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics 2014., 2014;252-71.
    Open DOISearch in Google Scholar
  2. 2. American Cancer Society.. Atlanta, GA: American Cancer Society; 2014.
    Search in Google Scholar
  3. 3. National Cancer Institute. Small cell lung cancer treatment. [citated 2015 Jan 15]. Available at:. 2014.
    Search in Google Scholar
  4. 4. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer.1992;1618-24.
    Open DOISearch in Google Scholar
  5. 5. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.1992;890-5.
    Open DOISearch in Google Scholar
  6. 6. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.1999;658-67.
    Open DOISearch in Google Scholar
  7. 7. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.2006;5441-7.
    Open DOISearch in Google Scholar
  8. 8. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.2007;2086-92.
    Open DOISearch in Google Scholar
  9. 9. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival.2009;1642-9.
    Open DOISearch in Google Scholar
  10. 10. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?2010;2324-32.
    Search in Google Scholar
  11. 11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.2009;1227-34.
    Open DOISearch in Google Scholar
  12. 12. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.2011; 6: e26646.
    Open DOISearch in Google Scholar
  13. 13. Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.2012;1537-41.
    Open DOISearch in Google Scholar
  14. 14. Imai H, Mori K, Wakuda K, Ono A, Akamatsu H, Shukuya T, et al. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.2015;61-6.
    Search in Google Scholar
  15. 15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.2000;205-16.
    Open DOISearch in Google Scholar
  16. 16. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.1988;1264-70.
    Open DOISearch in Google Scholar
  17. 17. Ebi N, Kubota K, Nishiwaki Y, Hojo F, Matsumoto T, Kakinuma R, et al. Second-line chemotherapy for relapsed small cell lung cancer.1997;166-9.
    Open DOISearch in Google Scholar
  18. 18. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.2006;741-6.
    Open DOISearch in Google Scholar
  19. 19. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.2009;311-7.
    Open DOISearch in Google Scholar
  20. 20. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.2011;1262-71.
    Open DOISearch in Google Scholar
  21. 21. Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Post progression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.2013;261-6.
    Open DOISearch in Google Scholar
  22. 22. Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, et al. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.2014;233-40.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/raon-2015-0037 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 409 - 415
Submitted on: Jan 31, 2015
Accepted on: Jul 6, 2015
Published on: Nov 27, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
chemoradiotherapy,
limited-stage disease small cell lung cancer,
overall survival,
post-progression survival,
progression-free survival
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Norimitsu Kasahara, Hisao Imai, Kyoichi Kaira, Keita Mori, Kazushige Wakuda, Akira Ono, Tetsuhiko Taira, Hirotsugu Kenmotsu, Hideyuki Harada, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, Masanobu Yamada, Toshiaki Takahashi, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 4 (December 2015)
Previous article